Neurokinin receptor antagonists

被引:28
作者
Leroy, V [1 ]
Mauser, P [1 ]
Gao, ZL [1 ]
Peet, NP [1 ]
机构
[1] Aventis Pharmaceuts, Bridgewater, NJ 08807 USA
关键词
asthma; depression; emesis; migraine; neurokinin; neurokinin receptor antagonist; substance P;
D O I
10.1517/13543784.9.4.735
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Studies on tachykinin peptides and the corresponding neurokinin receptors (NKr) have increased dramatically recently due to the discovery of selective, orally-active, metabolically stable and sometimes CNS penetrating NKr antagonists. After demonstrating the potential use for NKr antagonists in animal models, some compounds have recently progressed into clinical trials and a few results have been published. NKr antagonists have demonstrated efficacy for the treatment of emesis and depression, while results in other areas have been disappointing. Nonetheless, this area is coming to the exciting time of proof of concept in humans. Demonstration of the: involvement of tachykinin peptides in biological functions continues to grow, as do the potential indications for NKr antagonists. More drug candidates are undergoing clinical trials for various conditions and these results could widen the potential use for NKr antagonists.
引用
收藏
页码:735 / 746
页数:12
相关论文
共 68 条
  • [41] Neurokinin-3 receptor distribution in rat and human brain: An immunohistochemical study
    Mileusnic, D
    Lee, JM
    Magnuson, DJ
    Hejna, MJ
    Krause, JE
    Lorens, JB
    Lorens, SA
    [J]. NEUROSCIENCE, 1999, 89 (04) : 1269 - 1290
  • [42] Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist
    Navari, RM
    Reinhardt, RR
    Gralla, RJ
    Kris, MG
    Hesketh, PJ
    Khojasteh, A
    Kindler, H
    Grote, TH
    Pendergrass, K
    Grunberg, SM
    Carides, AD
    Gertz, BJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (03) : 190 - 195
  • [43] Norman B, 1998, CEPHALALGIA, V18, P407
  • [44] Nanomolar concentrations of neuropeptides induce histamine release from peritoneal mast cells of a substrain of Wistar rats
    Ogawa, K
    Nabe, T
    Yamamura, H
    Kohno, S
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 374 (02) : 285 - 291
  • [45] Correlation between binding characteristics and functional antagonism in human glioma cells by tachykinin NK1 receptor antagonists
    Palma, C
    Nardelli, F
    Manzini, S
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 374 (03) : 435 - 443
  • [46] Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors
    Palma, C
    Nardelli, F
    Manzini, S
    Maggi, CA
    [J]. BRITISH JOURNAL OF CANCER, 1999, 79 (02) : 236 - 243
  • [47] The tachykinin NK1 receptor.: Part II:: distribution and pathophysiological
    Quartara, L
    Maggi, CA
    [J]. NEUROPEPTIDES, 1998, 32 (01) : 1 - 49
  • [48] Quinlan KL, 1999, J IMMUNOL, V162, P1656
  • [49] REINHARDT RR, 1998, CLIN PHARM, V63, pP1
  • [50] Effects of tyrosine289phenylalanine mutation on binding and functional properties of the human tachykinin NK2 receptor stably expressed in Chinese hamster ovary cells
    Renzetti, AR
    Catalioto, RM
    Carloni, C
    Criscuoli, M
    Cucchi, P
    Giolitti, A
    Zappitelli, S
    Rotondaro, L
    Maggi, CA
    [J]. BIOCHEMICAL PHARMACOLOGY, 1999, 57 (08) : 899 - 906